Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Metronomic chemotherapy in human lung cancer: Mathematical modeling for an optimal schedule

Xavier Elharrar, Dominique Barbolosi, Joseph Ciccolini, Christophe Meille, Christian Faivre, Bruno Lacarelle, Nicolas André, Fabrice Barlesi
European Respiratory Journal 2015 46: PA4836; DOI: 10.1183/13993003.congress-2015.PA4836
Xavier Elharrar
1Multidisciplinary Oncology and Therapeutic Innovations, Assistance Publique Hôpitaux de Marseille, Marseille, France
2SMARTc Pharmacokinetics Unit, School of Pharmacy, Inserm S_911 CRO2, Aix Marseille University, Marseille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dominique Barbolosi
2SMARTc Pharmacokinetics Unit, School of Pharmacy, Inserm S_911 CRO2, Aix Marseille University, Marseille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Ciccolini
2SMARTc Pharmacokinetics Unit, School of Pharmacy, Inserm S_911 CRO2, Aix Marseille University, Marseille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christophe Meille
5Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences Roche Inoovation Center, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Faivre
2SMARTc Pharmacokinetics Unit, School of Pharmacy, Inserm S_911 CRO2, Aix Marseille University, Marseille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruno Lacarelle
2SMARTc Pharmacokinetics Unit, School of Pharmacy, Inserm S_911 CRO2, Aix Marseille University, Marseille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolas André
2SMARTc Pharmacokinetics Unit, School of Pharmacy, Inserm S_911 CRO2, Aix Marseille University, Marseille, France
4Pediatry Oncology Unit, Assistance Publique Hôpitaux de Marseille, Marseille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabrice Barlesi
1Multidisciplinary Oncology and Therapeutic Innovations, Assistance Publique Hôpitaux de Marseille, Marseille, France
2SMARTc Pharmacokinetics Unit, School of Pharmacy, Inserm S_911 CRO2, Aix Marseille University, Marseille, France
3CIC-CPCET Phase I Oncology Departement, Aix Marseille University, Marseille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Introduction: Improving the efficacy/toxicity balance of anticancer therapy is still challenging, especially in metastatic Non Small Cell Lung Cancer (NSCLC) patients. Metronomic oral Vinorelbine is known to have an activity in NSCLC, but all the studies published thus far were based upon a variety of empirical and suboptimal schedules, with inconsistent results.

Objective: To determine an optimized Vinorelbine metronomic schedule, using advanced mathematical modeling.

Methods: We transposed into mathematical language pharmacokinetics (PK) and pharmacodynamics (PD) efficacy and toxicities issues of oral vinorelbine. All the parameters were calibrated using previous data from preclinical and clinical trials with metronomic vinorelbine. To identify the schedule which achieves higher efficacy on tumor with acceptable tolerance, multiple metronomic modalities have been tested by simulation, using our PK/PD model and Monolix software.

Results: This study describes the development of our mathematical model and its consistency when simulating previously published data. In addition, mathematical modeling showed by simulation that a new metronomic protocol could lead to a better safety and efficacy profile. Whereas most of the trials with oral metronomic vinorelbine used a D1, D3, D5 schedule with a fixed dose of 50 mg, our mathematical model suggested an alternative D1, D2 and D4 innovative schedule with a dynamic intake of 60, 30 and 60 mg, respectively.

Conclusions: Mathematical modeling provides an opportunity to improve efficacy of metronomic regimen. A phase I trial will begin this year to prospectively confirm and to validate clinically this new metronomic protocol in NSCLC patients.

  • Lung cancer / Oncology
  • Pharmacology
  • Thoracic oncology
  • Copyright ©ERS 2015
Previous
Back to top
Vol 46 Issue suppl 59 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Metronomic chemotherapy in human lung cancer: Mathematical modeling for an optimal schedule
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Metronomic chemotherapy in human lung cancer: Mathematical modeling for an optimal schedule
Xavier Elharrar, Dominique Barbolosi, Joseph Ciccolini, Christophe Meille, Christian Faivre, Bruno Lacarelle, Nicolas André, Fabrice Barlesi
European Respiratory Journal Sep 2015, 46 (suppl 59) PA4836; DOI: 10.1183/13993003.congress-2015.PA4836

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Metronomic chemotherapy in human lung cancer: Mathematical modeling for an optimal schedule
Xavier Elharrar, Dominique Barbolosi, Joseph Ciccolini, Christophe Meille, Christian Faivre, Bruno Lacarelle, Nicolas André, Fabrice Barlesi
European Respiratory Journal Sep 2015, 46 (suppl 59) PA4836; DOI: 10.1183/13993003.congress-2015.PA4836
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Risk factors of febrile neutropenia induced by chemotherapy in lung cancer patients
  • Evaluation of response to chemotherapy with fiberoptic bronchoscopy in lung cancers
  • Equal efficacy of gefitinib in chemonaive lung adenocarcinoma patients with either exon 19 deletion or L858R point mutation
Show more 11.1 Lung Cancer

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society